Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease
Open accessAbstract
INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) is a membrane-bound glycoprotein that acts as a receptor but also exists in a soluble form. It has been recognized as a mediator of inflammation and considered a biomarker in inflammatory bowel disease (IBD). METHODS: We evaluated a prospectively recruited cohort, consisting of 101 patients with IBD, using validated clinical indexes; 22 patients with ulcerative colitis (UC) underwent endoscopic evaluation. Fecal DPP-4 (fDPP-4) levels were analyzed and correlated with clinical scores, Mayo endoscopic score (in UC patients), serum DPP-4, C-reactive protein, and fecal calprotectin. Immunohistochemical staining for DPP-4 in intestinal biopsies was also performed. RESULTS: When compared with remitters, median fDPP-4 levels were higher in patients with ileal Crohn's disease (CD) (7,584 [1,464–7,816] vs 2,104 [630–2,676] ng/mL, P = 0.015) and lower in patients with UC exhibiting clinical activity (1,213 [559–1,682] vs 7,814 [2,555–7,985] ng/mL, P < 0.001). Patients with UC presenting endoscopic activity also had lower levels than remitters (939 [559–1,420] vs 7,544 [4,531–7,940] ng/mL, P = 0.006). Fecal DPP-4 discriminated clinical activity from remission with areas under the curve of 0.76 (95% confidence interval [CI] 0.58–0.94, P = 0.015) and 0.80 (95% CI 0.68–0.93, P < 0.001) in CD and UC, respectively; it allowed to differentiate endoscopic activity in patients with UC, with areas under the curve of 0.84 (95% CI 0.63–1.00, P = 0.009). Immunohistochemical analysis revealed higher DPP-4 apical expression in UC remitters, but no statistically significant differences were revealed between patients with ileal CD. DISCUSSION: Our results suggest that fDPP-4 can be used as a biomarker of IBD activity, particularly in UC. The expression profiles in intestinal tissue might represent a functional compartmentalization of DPP-4 expression.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In two well-established rodent models of IBS that lead to visceral hyperalgesia, the enhanced visceromotor response to colorectal distension was reversed following administration of F. prausnitzii.
“Using two well-established rodent models of IBS that lead to visceral hyperalgesia in vivo, it was found that the enhanced visceromotor response to colorectal distension was reversed following administration of F. prausnitzii.”
From The emerging roles of bacterial proteases in intestinal diseases (2023) · cites this paper as [163]
Faecalibacterium prausnitzii is a potential source of anti-nociceptive mediators, including a PAR-4 activating serine protease.
“Subsequent studies have identified Faecalibacterium prausnitzii as a potential source of anti-nociceptive mediators, including a PAR-4 activating serine protease.”
From The emerging roles of bacterial proteases in intestinal diseases (2023) · cites this paper as [163]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Satsangi, J., Silverberg, M. S., Vermeire, S., & Colombel, J.-F. (2006) · Gut · doi:10.1136/gut.2005.082909 · Cited by 3,173 · see citing works
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,037 · see citing works
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
Harvey, R. F., & Bradshaw, J. M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92767-1 · Cited by 2,974 · see citing works
Peyrin‐Biroulet, L., Sandborn, W. J., Sands, B. E., Reinisch, W., Bemelman, W. A., Bryant, R. V., D’Haens, G., Dotan, I., Dubinsky, M. C., Feagan, B. G., et al. (2015) · The American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,843 · see citing works
Clinical Aspects and Pathophysiology of Inflammatory Bowel Disease
Hendrickson, B. A., Gokhale, R. R., & Cho, J. H. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.1.79-94.2002 · Cited by 630 · see citing works
Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders
Gorrell, M. D. (2005) · Clinical Science · doi:10.1042/cs20040302 · Cited by 335 · see citing works
Oravecz, T., Pall, M., Roderiquez, G., Gorrell, M. D., Ditto, M., Nguyen, N. Y., Boykins, R. A., Unsworth, E. J., & Norcross, M. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.11.1865 · Cited by 332 · see citing works
Lambeir, A., Proost, P., Durinx, C., Bal, G., Senten, K., Augustyns, K., Scharpé, S., Damme, J. V., & Meester, I. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103106200 · Cited by 271 · see citing works
Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV
Proost, P., Meester, I. D., Schols, D., Struyf, S., Lambeir, A., Wuyts, A., Opdenakker, G., Clercq, E. D., Scharpé, S., & Damme, J. V. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.13.7222 · Cited by 264 · see citing works
Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function
Ohnuma, K., Dang, N. H., & Morimoto, C. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.02.010 · Cited by 239 · see citing works
Matrix Metalloproteinases in Inflammatory Bowel Disease: An Update
O’Sullivan, S., Gilmer, J. F., & Medina, C. (2015) · Mediators of Inflammation · doi:10.1155/2015/964131 · Cited by 196 · see citing works
Circulating CD26 Is Negatively Associated with Inflammation in Human and Experimental Arthritis
Busso, N., Wagtmann, N. R., Herling, C., Chobaz-Péclat, V., Bischof-Delaloye, A., So, A. K.-L., & Grouzmann, E. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62266-3 · Cited by 191 · see citing works
Röhrborn, D., Eckel, J., & Sell, H. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.08.029 · Cited by 140 · see citing works
Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease
Xiao, Q., Boushey, R. P., Cino, M., Drucker, D. J., & Brubaker, P. L. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.278.4.r1057 · Cited by 111 · see citing works
Dipeptidyl Peptidase IV (DP IV, CD26) in Patients with Inflammatory Bowel Disease
Hildebrandt, M. (2001) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655201750422675 · Cited by 81 · see citing works
Significance of circulatory DPP4 activity in metabolic diseases
Nargis, T., & Chakrabarti, P. (2018) · IUBMB Life · doi:10.1002/iub.1709 · Cited by 81 · see citing works
Regional Expression of Epithelial Dipeptidyl Peptidase IV in the Human Intestines
Darmoul, D., Voisin, T., Couvineau, A., Rouyer‐Fessard, C., Salomon, R., Wang, Y., Swallow, D. M., & Laburthe, M. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2313 · Cited by 73 · see citing works
Bauvois, B., Sancéau, J., & Wietzerbin, J. (1992) · European Journal of Immunology · doi:10.1002/eji.1830220407 · Cited by 72 · see citing works
Kobayashi, H., Hosono, O., Mimori, T., Kawasaki, H., Dang, N. H., Tanaka, H., & Morimoto, C. (2002) · PubMed · Cited by 62 · see citing works
KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes
Nargis, T., Kumar, K. G., Ghosh, A. R., Sharma, A., Rudra, D., Sen, D., Chakrabarti, S., Mukhopadhyay, S., Ganguly, D., & Chakrabarti, P. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.004 · Cited by 59 · see citing works
Bauvois, B., Meester, I. D., Dumont, J., Rouillard, D., Zhao, H., & Bosmans, E. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690167 · Cited by 51 · see citing works
Dipeptidyl peptidase-4 expression is reduced in Crohn's disease
Moran, G. W., O’Neill, C. A., Padfield, P. J., & McLaughlin, J. T. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.04.006 · Cited by 46 · see citing works
Dipeptidyl-Peptidase IV Activity Is Correlated with Colorectal Cancer Prognosis
Larrinaga, G., Pérez, I., Sanz, B., Beitia, M., Errarte, P., Fernández‐Atutxa, A., Blanco, L., Etxezarraga, C., Gil, J., & Lopez, J. I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119436 · Cited by 41 · see citing works
Lopes, P., Afonso, J., Pinto-Lopes, R., Rocha, C., Lago, P. M., Gonçalves, R., de Sousa, H. T., Macedo, G., Dias, C. C., & Magro, F. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz319 · Cited by 27 · see citing works
Self-citation
Flagged first, then by citations
1 of the 25 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The emerging roles of bacterial proteases in intestinal diseases
Caminero, A., Guzman, M., Libertucci, J., & Lomax, A. E. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2181922 · Cited by 92 · see citing works
Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease
Huang, J., Liu, X., Wei, Y., Li, X., Gao, S., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830863 · Cited by 75 · see citing works
Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases
Hu, X., Wang, X., & Xue, X. (2022) · Molecules · doi:10.3390/molecules27144498 · Cited by 29 · see citing works
Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease
Jaenisch, S. E., Abbott, C. A., Gorrell, M. D., Bampton, P. A., Butler, R. N., & Yazbeck, R. (2022) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000452 · Cited by 16 · see citing works
The gut wall’s potential as a partner for precision oncology in immune checkpoint treatment
Lopez, S. H., Jalving, M., Fehrmann, R. S. N., Nagengast, W. B., de Vries, E. G. E., & de Haan, J. J. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102406 · Cited by 8 · see citing works
Chiara, L. D., Barcia-Castro, L., Gallardo‐Gómez, M., de la Cadena, M. P., Martínez-Zorzano, V. S., Rodrı́guez-Berrocal, F. J., Bujanda, L., Etxart, A., Castells, A., Balaguer, F., et al. (2022) · Cancers · doi:10.3390/cancers14194563 · Cited by 5 · see citing works
NLRP1B allele 2 does not respond to Val-boro-Pro (VbP) in intestinal epithelial cells
Mazzone, R. J., Winsor, N. J., Li, L. Y., Barry, K. T., Ranger, A., Goyal, S., Meade, J. J., Bruce, J. K., Philpott, D. J., Mogridge, J., et al. (2024) · Microbes and Infection · doi:10.1016/j.micinf.2024.105398 · Cited by 3 · see citing works
Gomes, S. F., Melo, F. J., Silva, R., Santiago, M., Estevinho, M. M., Dias, S., Dias, C. C., & Magro, F. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0139 · Cited by 2 · see citing works
Self-citationNLRP1B allele 2 does not respond to Val-boro-Pro (VbP) in the intestinal epitheliumPreprint
Mazzone, R. J., Winsor, N. J., Li, L. Y., Barry, K. T., Ranger, A., Goyal, S., Meade, J. J., Bruce, J. K., Philpott, D. J., Mogridge, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.18.604161
Hamid, H. H., Al-joda, B. M. S., & Almamory, A. J. (2025) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2025.4.1
Fecal DPP4 concentration reflects colonic injury in the TNBS-induced rat model of colitis
Gomes, S. F., Ferreira‐Duarte, M., Dias‐Pereira, P., Couto, J., Duarte‐Araújo, M., Morato, M., & Magro, F. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00030.2026
Self-citation
- Authors
- Pinto-Lopes, P., Melo, F., Afonso, J., Pinto-Lopes, R., Rocha, C., Melo, D., Macedo, G., Dias, C. C., Carneiro, F., Magro, F., & for the Portuguese IBD Study Group (GEDII)
- Affiliations
- Department of Internal Medicine, Faculty of Medicine, Centro Hospitalar Universitário São João, Porto, Portugal;
- Universidade do Porto (PT)
- Broomfield Hospital (GB)
- University of Lisbon (PT)
- Hospital de São João (PT)
- Corresponding author
- Magro, Fernando
- ORCID
- Venue
- Clinical and Translational Gastroenterology
- Published
- 2021-03
- Volume
- 12
- Issue
- 3
- Pages
- e00320
- ISSN
- 2155-384X (ISSN-L)
- PMC
- PMC7954374
- OpenAlex
- W3135671158
- Cited by
- 11
- References
- 25
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 5
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical and Translational Gastroenterology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Epidemiology › Microscopic Colitis
- Keywords
- dipeptidyl peptidase IV, fecal biomarkers, inflammatory bowel disease, ulcerative colitis, Crohn's disease, disease activity, endoscopic activity, remission, fecal calprotectin, C-reactive protein, diagnostic accuracy, inflammatory markers
- MeSH terms
- Adult, C-Reactive Protein, Colitis, Ulcerative, Colon, Crohn Disease, Feces, Female, Humans, Ileum, Intestinal Mucosa, Male, Middle Aged, Prospective Studies, Signal Transduction, Biomarkers, Endoscopy, Gastrointestinal, Dipeptidyl Peptidase 4, Leukocyte L1 Antigen Complex, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
